昊海生科(688366.SH)：擬取得亨泰視覺55%股權並取得並取得亨泰光學角膜塑形鏡產品myOK獨家經銷權
格隆匯 3 月 19日丨昊海生科(688366.SH)公佈，公司全資子公司上海昊海醫藥科技發展有限公司(“昊海發展”)與上海亨泰視覺科技有限公司(“亨泰視覺”或“目標公司”)、金亨泰(廈門)貿易有限公司(“金亨泰”或“原股東”)簽署《投資協議》，約定昊海發展以人民幣1500萬元受讓金亨泰持有的亨泰視覺10%股權，並以人民幣1000萬元增資款認購目標公司新增註冊資本人民幣1000萬元。(以上股權轉讓及增資合稱為“本次交易”)。
本次交易完成後，昊海發展以共計人民幣2500萬元總投資款獲得目標公司55%的股權，亨泰視覺成為昊海發展的控股子公司，納入公司合併報表。
同時，昊海生科全資子公司昊海生物科技控股有限公司(“昊海控股”)與亨泰光學股份有限公司(“亨泰光學”)、亨泰視覺簽署《獨家經銷合同》，約定亨泰光學授予亨泰視覺高端角膜塑形用硬性透氣接觸鏡產品(OK鏡)“邁兒康myOK”(“標的產品”)於中國大陸地區、期限為10年(截至2030年12月31日)的獨家經銷權；並持續授予亨泰視覺兒童近視管理及控制的光學鏡片“貝視得”於中國大陸地區的獨家經銷權。
目前，眼科業務已成為公司第一大業務板塊，公司已初步完成白內障手術核心耗材人工晶狀體及眼科粘彈劑的產業鏈佈局，並逐步推進近視矯正、眼表及眼底疾病診療產品佈局。在近視矯正領域，公司已有用於成人近視矯正的依鏡懸浮型有晶體眼後房屈光晶體(PRL)產品，而用於學齡兒童或青少年近視防控的新型角膜塑形鏡產品仍處於臨牀試驗階段，其他具備近視矯正功能的高透氧鞏膜鏡、軟性角膜接觸鏡等產品仍處於臨牀前研究階段。
亨泰光學成立於1976年，專注於從事定製化硬性隱形眼鏡的開發、製造、銷售以及隱形眼鏡護理產品的銷售，其研製的角膜塑形鏡產品已在國內市場獲批註冊、上市銷售多年。通過此次交易，公司將通過亨泰視覺獲得亨泰光學旗下標的產品在國內市場10年的獨家經銷權，進一步豐富公司在近視防控領域的產品佈局，鞏固和提高公司眼科業務競爭力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
